U.S. Food and Drug Administration authorized the restart after reviewing all safety data
MONDAY, Oct. 26, 2020 (HealthDay News) — Drugmakers AstraZeneca and Johnson & Johnson are ready to resume paused COVID-19 vaccine trials after health scares, CNN reported.
The AstraZeneca trial was stopped in early September, and the Johnson & Johnson trial was paused earlier this month.
The U.S. Food and Drug Administration authorized the restart after reviewing all the safety data, CNN reported. The AstraZeneca trial has already resumed in other countries. That trial was stopped after a volunteer in Britain developed an unexplained neurological condition. The Johnson & Johnson trial was halted because one participant had an “unexplained illness,” for which “no clear cause” was identified, the company said.
Government health officials and outside experts have said the holds are an example of how the safety process is protecting Americans from any potentially dangerous vaccines, CNN reported.
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season
Trends Reported in Vaccination Coverage for Adolescents for 2025
Considerable Gaps Reported in Care for Youth With Opioid Use Disorder
Nutritional Deficiencies Seen in Youth Taking GLP-1 Receptor Agonists
Youth Suicide Risk Linked to Community Firearm Violence
Social Media Warnings Could Discourage Use Among Teens, Young Adults